Archives

  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • b iframe width height src https www

    2020-08-02

    allowfullscreen>r> Conflicts of interest statement
    The authors declare that they have no conflicts of interests.
    Acknowledgements
    This study was supported by grants from the Ministry of Economy, Industry and Competitiveness, Government of Spain (SAF2014-56623-R and SAF2017-82689-R) and from the “Mutua Madrileña Investigación Biomédica” Foundation, Spain (FMM2011) to C. Montiel and F. Arnalich. J.L. Cedillo was recipient of a FPU fellowship (Ministry of Education, Culture and Sports, Government of Spain); A. Bordas and R. L. Arribas are recipients of a FPI fellowship (Autonomous University of Madrid); C. Martín-Sanchez was recipient of a FPI fellowship (Ministry of Economy, Industry and Competitiveness, Government of Spain).  Lung Cancer 128 (2019) 134–144
    Finally, M. Extremera and G. Atienza were hired with funds from the grants specified above. The authors thank Raquel Marcos-Hernández (Laboratory Technician) from Pathology Service, La Paz University Hospital, Madrid), for her help with the IHC experiments.
    References
    [3] C. Schaal, S. Chellappan, Nicotine-mediated regulation of nicotinic Cell Counting Kit-8 (CCK-8) receptors in non-small cell lung adenocarcinoma by E2F1 and STAT1 transcription factors, PLoS One 11 (2016) e0156451.
    [16] D.P. Locke, N. Archidiacono, D. Misceo, et al., Refinement of a chimpanzee peri-centric inversion breakpoint to a segmental duplication cluster, Genome Biol. 4 (2003) R50.
    [17] T.W. Costantini, X. Dang, R. Coimbra, B.P. Eliceiri, A. Baird, CHRFAM7A, a human-specific and partially duplicated alpha7-nicotinic acetylcholine receptor gene with the potential to specify a human-specific inflammatory response to injury, J.
    [18] A.M. de Lucas-Cerrillo, M.C. Maldifassi, F. Arnalich, et al., Function of partially duplicated human alpha7 nicotinic receptor subunit CHRFAM7A gene: potential implications for the cholinergic anti-inflammatory response, J. Biol. Chem. 286 (2011) 594–606.
    [21] J.L. Cedillo, F. Arnalich, C. Martin-Sanchez, et al., Usefulness of alpha7 nicotinic receptor messenger RNA levels in peripheral blood mononuclear cells as a marker for cholinergic antiinflammatory pathway activity in septic patients: results of a pilot study, J. Infect. Dis. 211 (2015) 146–155.
    [22] S. Saviozzi, F. Cordero, M. Lo Iacono, S. Novello, G.V. Scagliotti, R.A. Calogero, Selection of suitable reference genes for accurate normalization of gene expression profile studies in non-small cell lung cancer, BMC Cancer 6 (2006) 200.
    [29] W. Wang, H. Chin-Sheng, L.J. Kuo, et al., NNK enhances cell migration through alpha7-nicotinic acetylcholine receptor accompanied by increased of fibronectin expression in gastric cancer, Ann. Surg. Oncol. 19 (Suppl 3) (2012) S580–8. [30] A. Cucina, S. Dinicola, P. Coluccia, et al., Nicotine stimulates proliferation and in-hibits apoptosis in colon cancer cell lines through activation of survival pathways, J. Surg. Res. 178 (2012) 233–241.
    [41] Q. Zhang, X. Tang, Z.F. Zhang, R. Velikina, S. Shi, A.D. Le, Nicotine induces hy-poxia-inducible factor-1alpha expression in human lung cancer cells via nicotinic acetylcholine receptor-mediated signaling pathways, Clin. Cancer Res. 13 (2007) 4686–4694.
    Contents lists available at ScienceDirect
    Journal of Magnetism and Magnetic Materials
    journal homepage: www.elsevier.com/locate/jmmm
    Research articles
    Antibody conjugated onto surface modified magnetic nanoparticles for separation of HER2+ breast cancer cells 
    T
    Amir Hossein Haghighia, Zahra Faghihb, Mohammad Taghi Khorasanic, , Fatemeh Farjadiand
    a Department of Biomedical Engineering, Science and Research Branch, Islamic Azad University, Tehran, Iran
    b Shiraz Institute for Cancer Research, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran
    c Biomaterials Department, Iran Polymer and Petrochemical Institute, Tehran, Iran
    d Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
    Keywords:
    Bioseparation
    Magnetic nanoparticle
    Breast cancer
    Herceptin
    Breast cancer is one of the leading causes of death among women worldwide, therefore early diagnosis and monitoring the status of cancer are essential. In the present study we developed antibody-conjugated iron oxide magnetic nanoparticles (MNPs) with highly efficient potential to detect HER2-expressing cancer cells in blood, a compartment where tumor cells are very rare. The MNPs were first coated with (3-aminopropyl) trimethox-ysilane. Effective coating was checked by VSM, XRD, FT-IR, TGA, EDX, and SEM. Anti-HER2 antibody (Herceptin) was conjugated on the surface of silane-coated MNPs (MNP-Si). The affinity of antibody-conjugated MNPs (Ab/MNP-Si) for HER2-expressing cells was evaluated in the SK-BR-3 cell line as a breast cancer cell model. Different concentrations of SK-BR-3 cells were mixed with peripheral blood mononuclear cells and subjected to isolation with Ab/MNP-Si in a magnetic field. Separation efficiency, as determined by flow cyto-metry, was 77–98%. Further evaluation with fluorescence microscopy also confirmed the ability of Ab/MNP-Si to detect low numbers of SK-BR-3 cells in whole blood. Our results suggest that Ab/MNP-Si is a potentially useful tool to isolate circulating tumor cells by targeting tumor-specific surface receptors under a magnetic field, and may improve breast cancer diagnosis and monitoring.